Our vision
At TOLREMO, we address transcriptional non-oncogene addiction both as monotherapy and as combination regimens to transform targeted cancer treatments into long-term therapeutic solutions. By targeting transcriptional cell states, our goal is to arm physicians with novel anti-cancer therapies for better treatment success for their patients.
We are advancing our lead compound TT125-802, a best-in-class CBP/p300 bromodomain inhibitor, as monotherapy and in combination with targeted agents in solid tumors and haematological malignancies.
Leadership
Board of Directors
Scientific Advisory Board
In memoriam
Wilhelm Krek was one of TOLREMO’s co-founders and was Full Professor of Cell Biology at ETH Zurich since 2003. He was a world leader in cancer cell signaling and had worked at the Friedrich Miescher Institute for Biomedical Research (FMI), Basel, and at the Dana Farber Cancer Institute/Harvard Medical School in Boston. He co-founded the ETH Spin-off ProteoMedix AG, the Institute of Molecular Health Sciences, and the NEXUS Personalized Health Technologies Platform at ETH Zurich. He received several honors for his work on cell signaling and disease mechanisms, including the Robert Wenner Prize, the Friedrich Miescher Medal, the International Steiner Cancer Research Award, and the Swiss Bridge Award. He was an elected member of EMBO and the American Association for Cancer Research.
Willy was instrumental in laying the scientific foundation for the novel scientific principles that TOLREMO is based on. Despite his untimely passing, his contagious enthusiasm, his passion for science, and his visionary thinking will remain at the heart of the company.
Investors
